Standard Operating Procedure for CMC Deficiency Prevention Before Filing
| Department | Regulatory Affairs |
| SOP No. | RA/2026/718 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 13/04/2026 |
| Effective Date | 13/04/2026 |
| Review Date | 13/04/2028 |
Purpose
This Standard Operating Procedure (SOP) outlines the systematic approach to prevent Chemistry, Manufacturing, and Controls (CMC) deficiencies prior to regulatory filing. It aims to ensure the quality, completeness, and compliance of all CMC documentation and data submitted to regulatory authorities, thereby minimizing regulatory queries and delays. This SOP supports the control objective of maintaining high regulatory submission standards to expedite product approvals and uphold GMP compliance.
Scope
This SOP applies to all CMC related documentation preparation, review, verification, and approval activities for regulatory submissions across all product types, dosage forms, and manufacturing sites within the Regulatory Affairs department. It includes dossier compilation, data evaluation, validation summaries, manufacturing process descriptions, and quality control documentation. Activities outside the regulatory dossier preparation such as clinical data or non-CMC filings are excluded.
Responsibilities
The following roles are involved:
- Regulatory Affairs Associates – prepare and consolidate CMC documentation.
- Quality Assurance – perform quality reviews and ensure compliance.
- Subject Matter Experts (e.g., Manufacturing, QA, QC) – provide technical data and validation reports.
- Regulatory Affairs Manager – supervise and approve final dossier components.
- Document Control – ensure proper versioning and archiving of all relevant documents.
Accountability
The Regulatory Affairs Head is accountable for the overall implementation, adherence, periodic review, escalation of non-conformities, and ensuring the continued effectiveness of this SOP. They hold responsibility for ensuring that all filings meet regulatory expectations and company quality standards.
Procedure
The following comprehensive steps must be followed to ensure effective CMC deficiency prevention before filing:
- Preparation and Planning: Assemble a cross-functional team comprising Regulatory Affairs, Quality Assurance, Manufacturing, and Analytical Development representatives. Develop a filing timeline including milestones for data submission and dossier compilation.
- Document Collection: Gather all required CMC documents including batch records, validation reports, stability data, analytical method validations, manufacturing process descriptions, and change control documentation.
- Prerequisite Checks: Verify that all documents are current, GMP-compliant, and prepared according to regulatory guidelines. Ensure batch records and validation documents are complete and signed off by relevant departments.
- Quality Review: Conduct a thorough quality self-inspection to check for gaps, inconsistencies, or outdated data in the compiled dossier. Employ checklists tailored to the specific regulatory authority’s expectations.
- Gap Analysis and Deficiency Identification: Identify any potential deficiencies or missing information that could lead to regulatory queries or rejection. Document these findings in a formal gap analysis report.
- Corrective Actions: Engage relevant departments to address identified gaps promptly. This may include re-validation, additional testing, process requalification, or updating documentation.
- Final Review and Approval: Regulatory Affairs Manager reviews and approves the final dossier package ensuring all issues are satisfactorily addressed and documents are version-controlled.
- Regulatory Compliance Confirmation: Confirm that the dossier complies with current regulatory guidelines and pharmacopeial standards applicable to the product and region.
- Documentation and Record Retention: Archive all reviewed documents, gap analysis reports, corrective action records, and approval forms as per the company’s record retention policy for future audit readiness.
- Training and Awareness: Ensure all team members involved in dossier preparation are trained on current regulatory requirements, company SOP processes, and any revisions to prevent deficiencies.
- Continuous Improvement: After filing, review any regulatory feedback related to CMC aspects and update SOPs and process controls accordingly to reduce future filing deficiencies.
This procedure should be executed with utmost diligence, adherence to GMP principles, and collaborative communication among all stakeholders to prevent any CMC deficiencies before submission.
Abbreviations
CMC: Chemistry, Manufacturing, and Controls
GMP: Good Manufacturing Practice
QA: Quality Assurance
QC: Quality Control
SOP: Standard Operating Procedure
Documents
The following documents are essential for implementing this SOP:
- CMC Dossier Checklist (Annexure-1)
- Gap Analysis Report Template (Annexure-2)
- Corrective Action Request Form (Annexure-3)
References
International Council for Harmonisation (ICH) Guidelines Q7, Q8, Q9, and Q10;
FDA Guidance for Industry – Content and Format of Chemistry, Manufacturing, and Controls Documentation;
EMA Guideline on the Chemistry of Finished Pharmaceutical Products;
Company Quality Manual and Document Control Procedures;
Applicable Pharmacopoeia Standards (e.g., USP, EP).
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: CMC Dossier Checklist
Purpose: To ensure all required CMC documents and sections are included and complete prior to filing.
| Section | Document | Status | Comments |
|---|---|---|---|
| 1 | Manufacturing Process Description | Complete | Reviewed by Manufacturing SME |
| 2 | Batch Manufacturing Records | Complete | Sign-offs obtained |
| 3 | Analytical Method Validation Reports | Complete | Validated per latest protocols |
| 4 | Stability Study Reports | Provisionally Complete | Ongoing stability data included |
| 5 | Equipment Qualification Documents | Complete | Reviewed and archived |
| 6 | Change Control Records | Complete | All recent changes captured |
| 7 | Quality Control Specifications | Complete | Aligned with pharmacopeia |
| 8 | Validation Summaries | Complete | Process and cleaning validation included |
Annexure-2: Gap Analysis Report Template
Purpose: To document potential deficiencies identified during dossier review and to track resolutions.
| Reference Section | Identified Gap | Impact on Filing | Proposed Action | Status |
|---|---|---|---|---|
| Stability Data | Incomplete long-term data for new formulation | May delay approval | Provide bridging data or justify | In Progress |
| Analytical Validation | Outdated method SOP referenced | Potential audit finding | Update SOP to latest version | Closed |
| Batch Records | Missing signatures on 2 entries | Compliance risk | Retrieve documentation and confirm | Resolved |
Annexure-3: Corrective Action Request Form
Purpose: To formally request and document corrective actions for identified CMC deficiencies.
| CAR No. | CAR-2026-015 |
| Date Raised | 10/04/2026 |
| Originator Department | Regulatory Affairs |
| Deficiency Description | Incomplete stability data for API batch #40321 |
| Immediate Action Taken | Notified Analytical Development for expedited testing |
| Proposed Corrective Action | Complete stability study and update dossier section |
| Responsible Person | Manufacturing QA Lead |
| Deadline | 25/04/2026 |
| Verification of Effectiveness | Pending |
| Closure Date | |
| Approved By |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 13/04/2026 | 1.0 | Initial issue | New SOP creation |